4503 — Astellas Pharma Balance Sheet
0.000.00%
- ¥4tn
- ¥4tn
- ¥2tn
- 92
- 45
- 100
- 94
Annual balance sheet for Astellas Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 326,128 | 318,267 | 376,946 | 335,780 | 189,876 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 362,722 | 423,018 | 465,455 | 576,726 | 674,653 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 872,588 | 923,354 | 1,049,954 | 1,194,730 | 1,201,349 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 264,623 | 269,044 | 286,459 | 293,742 | 328,921 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,273,628 | 2,332,395 | 2,456,518 | 3,569,603 | 3,339,544 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 592,372 | 687,411 | 726,034 | 1,285,725 | 1,061,610 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 887,513 | 872,087 | 948,564 | 1,973,615 | 1,826,289 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1,386,115 | 1,460,308 | 1,507,954 | 1,595,988 | 1,513,255 |
| Total Liabilities & Shareholders' Equity | 2,273,628 | 2,332,395 | 2,456,518 | 3,569,603 | 3,339,544 |
| Total Common Shares Outstanding |